199 related articles for article (PubMed ID: 36265088)
1. Health Benefits and Cost-Effectiveness of Children's Oncology Group Breast Cancer Screening Guidelines for Chest-Irradiated Hodgkin Lymphoma Survivors.
Wong FL; Lee JM; Leisenring WM; Neglia JP; Howell RM; Smith SA; Oeffinger KC; Moskowitz CS; Henderson TO; Mertens A; Nathan PC; Yasui Y; Landier W; Armstrong GT; Robison LL; Bhatia S
J Clin Oncol; 2023 Feb; 41(5):1046-1058. PubMed ID: 36265088
[TBL] [Abstract][Full Text] [Related]
2. Clinical Benefits, Harms, and Cost-Effectiveness of Breast Cancer Screening for Survivors of Childhood Cancer Treated With Chest Radiation : A Comparative Modeling Study.
Yeh JM; Lowry KP; Schechter CB; Diller LR; Alagoz O; Armstrong GT; Hampton JM; Leisenring W; Liu Q; Mandelblatt JS; Miglioretti DL; Moskowitz CS; Oeffinger KC; Trentham-Dietz A; Stout NK
Ann Intern Med; 2020 Sep; 173(5):331-341. PubMed ID: 32628531
[TBL] [Abstract][Full Text] [Related]
3. Cost-Utility of Early Breast Cancer Surveillance in Survivors of Thoracic Radiation-Treated Adolescent Hodgkin Lymphoma.
Furzer J; Tessier L; Hodgson D; Cotton C; Nathan PC; Gupta S; Pechlivanoglou P
J Natl Cancer Inst; 2020 Jan; 112(1):63-70. PubMed ID: 31070751
[TBL] [Abstract][Full Text] [Related]
4. The cost-effectiveness of adding tomosynthesis to mammography-based breast cancer screening: an economic analysis.
Cressman S; Mar C; Sam J; Kan L; Lohrisch C; Spinelli JJ
CMAJ Open; 2021; 9(2):E443-E450. PubMed ID: 33888549
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of Breast Cancer Screening With Magnetic Resonance Imaging for Women at Familial Risk.
Geuzinge HA; Obdeijn IM; Rutgers EJT; Saadatmand S; Mann RM; Oosterwijk JC; Tollenaar RAEM; de Roy van Zuidewijn DBW; Lobbes MBI; van 't Riet M; Hooning MJ; Ausems MGEM; Loo CE; Wesseling J; Luiten EJT; Zonderland HM; Verhoef C; Heijnsdijk EAM; Tilanus-Linthorst MMA; de Koning HJ;
JAMA Oncol; 2020 Sep; 6(9):1381-1389. PubMed ID: 32729887
[TBL] [Abstract][Full Text] [Related]
6. Breast Cancer Screening Among Childhood Cancer Survivors Treated Without Chest Radiation: Clinical Benefits and Cost-Effectiveness.
Yeh JM; Lowry KP; Schechter CB; Diller LR; O'Brien G; Alagoz O; Armstrong GT; Hampton JM; Hudson MM; Leisenring W; Liu Q; Mandelblatt JS; Miglioretti DL; Moskowitz CS; Nathan PC; Neglia JP; Oeffinger KC; Trentham-Dietz A; Stout NK
J Natl Cancer Inst; 2022 Feb; 114(2):235-244. PubMed ID: 34324686
[TBL] [Abstract][Full Text] [Related]
7. Impact of Early Breast Cancer Screening on Mortality Among Young Survivors of Childhood Hodgkin's Lymphoma.
Hodgson DC; Cotton C; Crystal P; Nathan PC
J Natl Cancer Inst; 2016 Jul; 108(7):. PubMed ID: 26933010
[TBL] [Abstract][Full Text] [Related]
8. Breast Imaging in Women Previously Irradiated for Hodgkin Lymphoma.
Horst KC; Fero KE; Hancock SL; Advani RH; Ikeda DM; Daniel B; Rosenberg SA; Donaldson SS; Hoppe RT
Am J Clin Oncol; 2016 Apr; 39(2):114-9. PubMed ID: 24390271
[TBL] [Abstract][Full Text] [Related]
9. The cost-effectiveness of digital breast tomosynthesis in a population breast cancer screening program.
Wang J; Phi XA; Greuter MJW; Daszczuk AM; Feenstra TL; Pijnappel RM; Vermeulen KM; Buls N; Houssami N; Lu W; de Bock GH
Eur Radiol; 2020 Oct; 30(10):5437-5445. PubMed ID: 32382844
[TBL] [Abstract][Full Text] [Related]
10. Economic evaluation of supplemental breast cancer screening modalities to mammography or digital breast tomosynthesis in women with heterogeneously and extremely dense breasts and average or intermediate breast cancer risk in US healthcare.
Blankenburg M; Sánchez-Collado I; Soyemi BO; Åkerborg Ö; Caleyachetty A; Harris J; Morris E; Newstead G; Lobig F
J Med Econ; 2023; 26(1):850-861. PubMed ID: 37278659
[TBL] [Abstract][Full Text] [Related]
11. Low-dose chest computed tomography for lung cancer screening among Hodgkin lymphoma survivors: a cost-effectiveness analysis.
Wattson DA; Hunink MG; DiPiro PJ; Das P; Hodgson DC; Mauch PM; Ng AK
Int J Radiat Oncol Biol Phys; 2014 Oct; 90(2):344-53. PubMed ID: 25104066
[TBL] [Abstract][Full Text] [Related]
12. Should women with a BRCA1/2 mutation aged 60 and older be offered intensified breast cancer screening? - A cost-effectiveness analysis.
Phi XA; Greuter MJW; Obdeijn IM; Oosterwijk JC; Feenstra TL; Houssami N; de Bock GH
Breast; 2019 Jun; 45():82-88. PubMed ID: 30904701
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of MRI compared to mammography for breast cancer screening in a high risk population.
Moore SG; Shenoy PJ; Fanucchi L; Tumeh JW; Flowers CR
BMC Health Serv Res; 2009 Jan; 9():9. PubMed ID: 19144138
[TBL] [Abstract][Full Text] [Related]
14. Long-Term Outcomes and Cost-Effectiveness of Breast Cancer Screening With Digital Breast Tomosynthesis in the United States.
Lowry KP; Trentham-Dietz A; Schechter CB; Alagoz O; Barlow WE; Burnside ES; Conant EF; Hampton JM; Huang H; Kerlikowske K; Lee SJ; Miglioretti DL; Sprague BL; Tosteson ANA; Yaffe MJ; Stout NK
J Natl Cancer Inst; 2020 Jun; 112(6):582-589. PubMed ID: 31503283
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of Digital Breast Tomosynthesis in Population-based Breast Cancer Screening: A Probabilistic Sensitivity Analysis.
Sankatsing VDV; Juraniec K; Grimm SE; Joore MA; Pijnappel RM; de Koning HJ; van Ravesteyn NT
Radiology; 2020 Oct; 297(1):40-48. PubMed ID: 32749212
[TBL] [Abstract][Full Text] [Related]
16. Prospective study of the efficacy of breast magnetic resonance imaging and mammographic screening in survivors of Hodgkin lymphoma.
Ng AK; Garber JE; Diller LR; Birdwell RL; Feng Y; Neuberg DS; Silver B; Fisher DC; Marcus KJ; Mauch PM
J Clin Oncol; 2013 Jun; 31(18):2282-8. PubMed ID: 23610104
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of MRI for breast cancer screening in BRCA1/2 mutation carriers.
Pataky R; Armstrong L; Chia S; Coldman AJ; Kim-Sing C; McGillivray B; Scott J; Wilson CM; Peacock S
BMC Cancer; 2013 Jul; 13():339. PubMed ID: 23837641
[TBL] [Abstract][Full Text] [Related]
18. Cost-Effectiveness of Magnetic Resonance Imaging Screening for Women With Extremely Dense Breast Tissue.
Geuzinge HA; Bakker MF; Heijnsdijk EAM; van Ravesteyn NT; Veldhuis WB; Pijnappel RM; de Lange SV; Emaus MJ; Mann RM; Monninkhof EM; de Koekkoek-Doll PK; van Gils CH; de Koning HJ;
J Natl Cancer Inst; 2021 Nov; 113(11):1476-1483. PubMed ID: 34585249
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness and budget impact analyses of colorectal cancer screenings in a low- and middle-income country: example from Thailand.
Phisalprapa P; Supakankunti S; Chaiyakunapruk N
J Med Econ; 2019 Dec; 22(12):1351-1361. PubMed ID: 31560247
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
